Right Ventricular Dysfunction and Adverse Outcomes after Renal Transplantation

Megan S. Joseph

Francis Tinney Jr.
*Henry Ford Health System, FTINNEY1@hfhs.org*

Abhijit Naik

Raviprasenna Parusuraman

Milagros Samaniego-Picota
*Henry Ford Health System, MSamani1@hfhs.org*

*See next page for additional authors*

Follow this and additional works at: [https://scholarlycommons.henryford.com/surgery_articles](https://scholarlycommons.henryford.com/surgery_articles)

**Recommended Citation**

Joseph MS, Tinney F, Naik A, Parusuraman R, Samaniego-Picota M, and Bhave NM. Right Ventricular Dysfunction and Adverse Outcomes after Renal Transplantation. Cardiorenal Med 2021; 11(2):109-118.

This Article is brought to you for free and open access by the Surgery at Henry Ford Health System Scholarly Commons. It has been accepted for inclusion in Surgery Articles by an authorized administrator of Henry Ford Health System Scholarly Commons.
Authors

Megan S. Joseph, Francis Tinney Jr., Abhijit Naik, Raviprasenna Parashuraman, Milagros Samaniego-Picota, and Nicole M. Bhave
Right Ventricular Dysfunction and Adverse Outcomes after Renal Transplantation

Megan S. Joseph\textsuperscript{a}  Francis Tinney\textsuperscript{b}  Abhijit Naik\textsuperscript{c}  Raviprasenna Parasuraman\textsuperscript{c}  Milagros Samaniego-Picota\textsuperscript{d}  Nicole M. Bhave\textsuperscript{a}

\textsuperscript{a}Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan Medical School and Michigan Medicine, Ann Arbor, MI, USA; \textsuperscript{b}Department of Surgery, Henry Ford Health System, Detroit, MI, USA; \textsuperscript{c}Division of Nephrology, Department of Internal Medicine, University of Michigan Medical School and Michigan Medicine, Ann Arbor, MI, USA; \textsuperscript{d}Division of Nephrology, Department of Internal Medicine, Henry Ford Health System, Detroit, MI, USA

Keywords
End-stage renal disease · Right ventricular dilation · Right ventricular dysfunction · Renal transplant

Abstract

Introduction: Pulmonary hypertension is common among patients with end-stage renal disease, although data regarding the impact of right ventricular (RV) failure on postoperative outcomes remain limited. We hypothesized that echocardiographic findings of RV dilation and dysfunction are associated with adverse clinical outcomes after renal transplant.

Methods: A retrospective review of adult renal transplant recipients at a single institution from January 2008 to June 2010 was conducted. Patients with transthoracic echocardiograms (TTEs) within 1 year leading up to transplant were included. The primary end point was a composite of delayed graft function, graft failure, and all-cause mortality. Eighty patients were included. Mean follow-up time was 9.4 ± 0.8 years. Eight patients (100%) with qualitative RV dysfunction met the primary end point, while 39/65 patients (60.0%) without RV dysfunction met the end point ($p = 0.026$). Qualitative RV dilation was associated with a significantly shorter time to all-cause graft failure ($p = 0.03$) and death ($p = 0.048$). RV systolic pressure was not measurable in 45/80 patients (56%) and was not associated with outcomes in the remaining patients. Conclusion: RV dilation and dysfunction are associated with adverse outcomes after renal transplant. TTE assessment of RV size and function should be a standard part of the pre-kidney transplant cardiovascular risk assessment.

Introduction

Cardiovascular disease is the leading cause of morbidity and mortality in patients with end-stage renal disease (ESRD) \cite{1, 2}. Data from the United States Renal Data System have demonstrated that cardiovascular disease accounts for 31% of patient deaths with a functioning graft \cite{3}. Much of the literature and clinical effort regarding preoperative risk stratification in this population focuses on ischemic heart disease and left-sided heart fail-
The prevalence of pulmonary hypertension (PH) in ESRD has been reported to be about 33% [4], based on echocardiographic evidence of elevated right ventricular systolic pressure (RVSP). While elevated pretransplant RVSP has been associated with the adverse posttransplant outcomes in a number of studies [5], data regarding the impact of right ventricular (RV) failure on postoperative outcomes remain limited [1, 6].

Transthoracic echocardiography (TTE) is a widely available, relatively rapid, and very well-tolerated examination that is commonly used as a noninvasive screening tool for PH [7]. As outcomes in PH are closely linked to RV systolic function [8], assessment of RV size and function by TTE is invaluable for prognostication and management. We hypothesized that preoperative RV dilation and dysfunction as observed on TTE is associated with worse outcomes after renal transplantation, including delayed graft function, graft failure, and all-cause mortality.

**Materials and Methods**

**Study Population**

A retrospective review of adults receiving renal transplants at the University of Michigan from January 2008 to June 2010 was conducted. Patients who had TTEs, performed at our institution within 1 year prior to transplant were included in the analysis. Patients undergoing double organ transplant (heart–kidney, liver–kidney, or kidney–pancreas) were excluded. The University of Michigan institutional review board approved the study. After transplantation, patients were treated with a standard triple immunosuppression protocol consisting of tacrolimus, mycophenolate mofetil, and maintenance-dose prednisone therapy. The primary end point was a composite of delayed graft function, graft failure, and all-cause mortality. Delayed graft function was defined as the need for hemodialysis within 1 week after transplantation.

**Clinical Data Collection**

Standard demographic and anthropometric data, laboratory test results, mode of dialysis, pretransplant medications, and outcomes data were collected from the electronic medical records. Clinical outcomes were extracted from the electronic medical records (Epic, Epic Systems Corporation, Madison, WI, USA) and from the University of Michigan Organ Transplant Information System (OTIS), which is a comprehensive transplant database. Preoperative hypotension was defined as systolic blood pressure <90 mm Hg at the final preoperative clinic appointment.

**Echocardiography**

Images were acquired using standard echocardiographic machines (Philips of Andover, MA, USA and Siemens of Washington, DC, USA). Complete TTEs with 2-dimensional imaging and Doppler evaluation were performed according to the standard clinical protocol. If multiple studies were obtained for a given patient within the year prior to transplantation, the study that occurred closest to the transplant was analyzed. All measurements were made by a blinded expert echocardiographer (NB). Standard linear measurements of the left ventricle (LV) and left atrium were made in the parasternal long-axis view. Left ventricular end-systolic and end-diastolic volumes were obtained using Simpson’s method of discs, based on tracings in the apical 2-chamber and 4-chamber views. These volumes were used to calculate the biplane left ventricular ejection fraction (LVEF) as follows:

\[ \text{LVEF} = \frac{[\text{LV end-diastolic volume} - \text{LV end-systolic volume}]}{\text{LV end-diastolic volume}} \times 100\% \]

LVEF was also estimated visually. Left ventricular systolic dysfunction was defined as LVEF <50%, with calculated LVEF used preferentially over visually estimated LVEF, unless calculation was not possible due to limited image quality.

RV linear measurements were made in the apical 4-chamber view. As per the current guidelines, the upper limits of normal for these parameters are as follows: RV basal diameter, 41 mm; RV mid-cavity diameter, 35 mm; and RV length, 83 mm [10]. Qualitative RV dilation and dysfunction were adjudicated by the echocar-

**Table 1. Baseline demographics of the study population (N = 80)**

| Variable                                    | Mean value or patients, n (%) |
|---------------------------------------------|-------------------------------|
| Age: mean ± SD, years                       | 51.3±14.2                     |
| Gender                                      |                               |
| Male                                        | 58 (72.5)                     |
| Female                                      | 22 (27.5)                     |
| Primary etiology of renal failure           |                               |
| Diabetes mellitus                           | 21 (26.3)                     |
| Hypertension                                | 7 (8.8)                       |
| Multifactorial (DM & HTN)                   | 6 (7.5)                       |
| Glomerulonephritis                          | 21 (26.3)                     |
| PCKD                                        | 8 (10.0)                      |
| Drug toxicity                               | 7 (8.8)                       |
| Urologic issue                              | 5 (6.3)                       |
| Other                                        | 5 (6.3)                       |
| Dialysis-dependent                          |                                |
| On hemodialysis                             | 62 (77.5)                     |
| On peritoneal dialysis                      | 54 (67.5)                     |
| AV fistula present                          | 8 (10)                        |
| Duration of dialysis, years: mean±SD        | 2.8±2.6                       |
| Diabetes mellitus                           | 33 (41.3)                     |
| Chronic systemic hypertension               | 68 (85.0)                     |
| Anemia                                      | 65 (81.3)                     |
| Type of renal transplant                    |                               |
| Living unrelated donor                      | 16 (20.0)                     |
| Living related donor                        | 16 (20.0)                     |
| Deceased unrelated donor                    | 48 (60.0)                     |
| Hypotension at the time of transplant       | 10 (12.5)                     |
| History of CAD                              | 25 (31.3)                     |
| History of smoking                          | 37 (46.3)                     |

DM, diabetes mellitus; HTN, hypertension; SD, standard deviation; PCKD, polycystic kidney disease; AV, arteriovenous; CAD, coronary artery disease.
Right Ventricular Dysfunction and Renal Transplant Outcomes

Table 2. Summary of echocardiographic findings

| Variable                        | Mean value ± SD or patients, n (%) | in all patients (N = 80) | in patients who met the primary end point (N = 52) | in patients who did not meet the primary end point (N = 28) | Patients for whom data could not be obtained, n (%) |
|---------------------------------|------------------------------------|--------------------------|-----------------------------------------------|----------------------------------------------------------|-----------------------------------------------------|
| LV size                         |                                    |                          |                                               |                                                          |                                                     |
| LVIDd (mm ± SD)                 | 51±7.7                             | 51±8.0                   | 49±7.5                                       | 2 (2.5)                                                  |                                                     |
| LV ejection fraction <50%, n (%)| 9 (11.3)                           | 8 (15.4)*                | 1 (3.6)                                      | 2 (2.5)                                                  |                                                     |
| RV size                         |                                    |                          |                                               |                                                          |                                                     |
| RV basal diameter (mm ± SD)     | 39±7.3                             | 40±7.5                   | 38±6.8                                       | 12 (15)                                                  |                                                     |
| RV mid-cavity diameter (mm ± SD)| 27±6.3                             | 27±7.0                   | 26±5.3                                       | 22 (27.5)                                                |                                                     |
| RV length (mm ± SD)             | 76±9.2                             | 77±8.7                   | 75±9.9                                       | 12 (15)                                                  |                                                     |
| Qualitative RV dilation, n (%)  | 16 (20)                            | 13 (25)                  | 3 (10.7)                                     | 5 (6.3)                                                  |                                                     |
| RV function, n (%)              |                                    |                          |                                               |                                                          |                                                     |
| Qualitative RV dysfunction      | 8 (10)                             | 8 (15.4)*                | 0 (0)                                        | 7 (8.8)                                                  |                                                     |
| LA size                         |                                    |                          |                                               |                                                          |                                                     |
| LA volume (mL ± SD)             | 80±33.6                            | 82±32.1†                 | 76±36.3                                      | 3 (3.8)                                                  |                                                     |
| LA AP diameter (mm ± SD)        | 44±7.4                             | 45±7.3‡                  | 42±7.3                                       | 0 (0)                                                    |                                                     |
| RA area (cm² ± SD)              | 18±7.0                             | 18±6.2                   | 18±8.3                                       | 10 (12.5)                                                |                                                     |
| RVSP (mm Hg ± SD)               | 31±9.0                             | 32±9.5                   | 30±9.5                                       | 45 (56.3)                                                |                                                     |
| Moderate or greater tricuspid regurgitation, n (%) | 2 (2.5) | 1 (1.9) | 1 (3.6) | 0 (0) |                                                     |
| E/e’ ≥ 15, n (%)                | 7 (8.8)                            | 6 (11.5)‡                | 1 (3.6)                                      | 19 (23.8)                                                |                                                     |

SD, standard deviation; LVIDd, left ventricular internal diameter at end-diastole; LV, left ventricular; AP, antero-posterior; RV, right ventricular; LA, left atrial; RA, right atrial; RVSP, right ventricular systolic pressure. * p = 0.026 for difference between patients who did and did not meet the primary end point. † p = 0.486 for difference. ‡ p = 0.061 for difference. ¶ p = 0.10 for difference. § p = 0.13 for difference.

Results

Subject Characteristics

A total of 80 adult kidney transplant patients were included in the study, with a mean follow-up time of 9.4 ± 0.8 years. Baseline demographics of the study population are presented in Table 1. The mean age of transplant recipients was 51.3 ± 14.2 years (range, 19–75 years). The most common etiologies of renal failure were diabetes mellitus (21 patients, 26.3%), glomerulonephritis (21 patients, 26.3%), and polycystic kidney disease (8 patients, 10.0%). A majority of transplant recipients (62 patients, 77.5%) were dialysis-dependent leading up to transplant, with the most common modality being hemodialysis (54 patients, 67.5%). The mean duration of dialysis prior to transplant was 2.8 ± 2.6 years. Over the follow-up period,
20 patients (25.0%) had delayed graft function, 44 patients (55.0%) had renal failure, and 34 patients (42.5%) died.

There were 10 patients with preoperative hypotension, and all of them (100%) met the primary composite end point, as compared to 57.5% (23/40) of normotensive patients and 66.7% (18/27) of hypertensive patients ($p = 0.039$ for difference). Longer dialysis duration prior to transplant was also associated with a higher risk of the primary end point (mean dialysis duration was $3.3 \pm 2.4$ years for those meeting the end point vs. $1.8 \pm 2.7$ years for others, $p = 0.016$).

**Echocardiographic Parameters**

Echocardiographic findings are presented in Table 2. In our population, the average left ventricular internal diameter at end-diastole (LVIDd) was $51 \pm 7.7$ mm, and 9 patients (11.3%) had LVEF <50%. The mean RV basal...

### Table 3. Echocardiographic findings according to AV fistula status

| Variable                          | Patients, n (%) | $p$ value |
|-----------------------------------|-----------------|-----------|
|                                   | in patients with AV fistulas ($n = 39$) | in patients without AV fistulas ($n = 41$) | |
| LV dilation ($n = 13$)            | 6 (46.2) | 7 (53.8) | 0.90 |
| LV ejection fraction <50% ($n = 9$) | 5 (55.6) | 4 (44.4) | 0.73 |
| Qualitative RV dilation ($n = 16$) | 9 (56.3) | 7 (43.7) | 0.41 |
| Qualitative RV dysfunction ($n = 8$) | 5 (62.5) | 3 (37.5) | 0.46 |

AV, arteriovenous; LV, left ventricular; RV, right ventricular.

### Table 4. Baseline and echocardiographic findings in patients with qualitative RV dysfunction

| Variable                                    | Mean value ± SD or patients, n (%) |
|---------------------------------------------|------------------------------------|
|                                            | in patients with RV dysfunction ($N = 8$) | in patients without RV dysfunction ($N = 65$) |
| Met primary end point, n (%)                | 8 (100.0) | 39 (60.0) |
| Time on dialysis, years: mean ± SD          | 3.1±2.7 | 2.8±2.7 |
| Hypotension, n (%)                          | 3 (37.5)* | 5 (7.7) |
| LV size                                     |                                   |
| LVIDd (mm ± SD)                             | 48±3.1 | 51±8.9 |
| LV function, n (%)                          |                                   |
| LV ejection fraction <50%                   | 1 (12.5) | 6 (9.2) |
| RV size                                     |                                   |
| RV basal diameter (mm ± SD)                 | 48±4.6† | 38±6.7 |
| RV mid-cavity diameter (mm ± SD)            | 33±5.7 | 26±6.1 |
| RV length (mm ± SD)                         | 80±11.7 | 76±9.1 |
| Qualitative RV dilation, n (%)              | 6 (75.0)‡ | 10 (15.4) |
| LA size                                     |                                   |
| LA volume (mL ± SD)                         | 85±24.5 | 79±35.0 |
| LA AP diameter (mm ± SD)                    | 49±8.7 | 43±7.1 |
| RA area (cm² ± SD)                          | 24±10.5 | 18±6.5 |
| RVSP (mm Hg ± SD)                           | 34±12.3 | 30±9.1 |
| Moderate or greater tricuspid regurgitation, n (%) | 1 (12.5)§ | 1 (1.5) |

SD, standard deviation; LVIDd, left ventricular internal diameter at end-diastole; LV, left ventricular; RV, right ventricular; AP, antero-posterior; LA, left atrial; RA, right atrial; RVSP, right ventricular systolic pressure. * $p = 0.01$ for difference between patients who did and did not have RV dysfunction. † $p = 0.02$ for difference. ‡ $p = 0.0001$ for difference. § $p = 0.04$ for difference.
diameter was $39 \pm 7.3$ mm, RV mid-cavity diameter was $27 \pm 6.3$ mm, and RV length was $76 \pm 9.2$ mm. The average right atrial area was $18 \pm 7.0$ cm$^2$. Seven patients (8.8%) had $E/e' \geq 15$. Eight patients (10%) had qualitative RV dysfunction and 16 patients (20%) had qualitative RV dilation. The presence of an arteriovenous (AV) fistula was not significantly associated with LV dilation, LV dysfunction, RV dilation, or RV dysfunction (Table 3). Duration of dialysis was not significantly associated with RV dysfunction or RV dilation ($p = 0.76$ and $p = 0.79$, respectively).

RV function could be assessed qualitatively in 73/80 patients (91.3%). Qualitative RV dysfunction was associated with a significantly higher risk of the primary end point ($p = 0.026$). All 8 patients (100%) with qualitative RV dysfunction met the primary end point, while 39/65 patients (60.0%) without RV dysfunction met the end point. Of the patients with RV dysfunction, 3 patients had delayed graft function, 6 patients developed graft failure, and 5 patients died. Among patients with RV dysfunction, 1/8 patients (12.5%) had LV dysfunction as well, as compared with 6/65 patients without RV dysfunction (9.2%, $p = 0.78$ for comparison). Patients with RV dysfunction had significantly more dilated RVs than those without RV dysfunction (mean RV basal diameter 48 vs. 38 mm, $p = 0.02$). Mean RA area was larger among patients with RV dysfunction, but this difference was not statistically significant (24 vs. 18 cm$^2$, $p = 0.25$). Preoperative hypotension was more common among patients with RV dysfunction, but this difference was not statistically significant (24 vs. 18 cm$^2$, $p = 0.25$). Preoperative hypotension was more common among patients with RV dysfunction (3/8 patients, 37.5%, vs. 5/65 patients, 7.7% of patients without RV dysfunction, $p = 0.01$; Table 4).

RV basal diameter was measurable in 68/80 patients (85.0%). Patients in the highest quartile of RV basal diameter had a shorter time to all-cause graft failure and death compared to patients in the lowest quartile, though these
differences did not meet statistical significance ($p = 0.09$ for both; Fig. 1). RV dilation could be assessed qualitatively in 75/80 patients (93.8%). Qualitative RV dilation was associated with a significantly shorter time to all-cause graft failure ($p = 0.03$) as well as a significantly shorter time to death ($p = 0.048$) (Fig. 2).

Notably, RVSP based on tricuspid regurgitation velocity was not possible to be measured in 45/80 (56%) of patients. RVSP did not differ significantly in patients who did and did not meet the primary end point (mean $32 \pm 9.5$ vs. $30 \pm 9.5$ mm Hg, $p = 0.39$). RVSP was moderately correlated with RV basal diameter ($r = 0.57$, $p = 0.001$) (Fig. 3). The prevalence of moderate or greater tricuspid regurgitation in our study was 2.5%.

**Discussion**

A number of echocardiographic studies have demonstrated that the prevalence of PH is high among patients with ESRD [12–14]. There are many potential causes for the increased prevalence in this population, including left ventricular systolic and/or diastolic dysfunction, chronic volume overload due to inadequate ultrafiltration, high cardiac output in the setting of AV fistula and/or chronic anemia, and sleep apnea [15]. Interestingly, in a study of 76 patients with ESRD, Abdelwhab and Elshinnawy [13] demonstrated that the prevalence of PH (defined as an estimated RVSP of $>35$ mm Hg on TTE) was high regardless of whether the patients were managed with hemodi-
Right Ventricular Dysfunction and Renal Transplant Outcomes

analysis (44.4%) or had not yet initiated dialysis and were managed with medications alone (32.3%).

Multiple studies have shown the presence of PH to be a strong prognostic indicator in the ESRD and posttransplant populations. Stallworthy et al. [16] performed a retrospective review of 739 patients evaluated for renal transplantation and found that PH and/or RV dysfunction was significantly associated with all-cause mortality (hazard ratio 1.91, \( p = 0.001 \)). Zlotnick et al. [17] showed that RVSP ≥35 mm Hg was associated with early graft failure in deceased donor recipients (43% in patients with elevated RVSP vs. 6% in those with normal RVSP, \( p = 0.002 \)). Issa et al. [18] found that a markedly elevated RVSP of >50 mm Hg was associated with reduced survival post-transplantation (\( p = 0.06 \)). However, RVSP could not be measured in a large number of patients (36/94 [38.3%] for Zlotnick et al. [17] and 109/324 [33.6%] for Issa et al. [18]). Finally, Caughey et al. [19] considered that left atrial pressure might be associated with outcomes in patients with PH who underwent kidney transplantation. They found that 5-year mortality was higher in patients with PH in the absence of elevated left atrial pressure, suggesting that patients with significant pulmonary vascular disease are at highest risk [19].

RV dilation and dysfunction are strong prognostic indicators in PH [8], and among patients beginning hemodialysis, RV dysfunction has been shown to be independently associated with mortality [20]. Cardiovascular-related hospitalizations and events occur more frequently after a long interdialytic interval [21]. Tsiolons et al. [22] measured the echocardiographic parameters of LV and RV function at the end of 3- and 2-day interdialytic intervals. They found that while LV systolic function remains unchanged, there was a significant increase in inferior vena cava diameter, RA volume, and RVSP during the 3-day interval, suggesting that right heart failure is a major driver of poor outcomes. They hypothesized that unlike the LV, which has greater wall thickness, the RV is highly susceptible to volume overload [22]. Furthermore, hemodialysis involves large and frequent fluid shifts. RV dysfunction has been associated with intradialytic hypotension, which results in myocardial stunning and ischemia [23]. While we found that duration of dialysis was not significantly associated with development of RV dysfunction or RV dilation, this may be a consequence of evaluating a small study population. Interestingly, while having an AV fistula is a recognized risk factor for high-output heart failure, having an AV fistula was not associated with a significantly higher rate of LV dilation, LV dysfunction, RV dilation, or RV dysfunction in our small study [24]. This may also be a consequence of evaluating a small study population.

The goal of our study was to assess whether markers of RV dilation and dysfunction are associated with poor outcomes following renal transplant, including delayed graft function, graft failure, and all-cause mortality. Particularly, important findings include the high prevalence of RV dysfunction and dilation in this population (10 and 20%, respectively) and the fact that patients with qualitative RV dysfunction had a significantly higher likelihood of reaching the primary end point. As discussed above, while there are many potential causes of RV dysfunction in patients with ESRD, in our study population the exact

![Fig. 3. Correlation of RVSP with RV basal diameter. RVSP, right ventricular systolic pressure; RV, right ventricular.](image-url)
causes of RV dysfunction were not known. Furthermore, RV dilation was associated with shorter time to all-cause graft failure and shorter time to death. There are multiple mechanisms by which RV dilation and dysfunction may contribute to graft failure, including venous congestion and low cardiac output. A retrospective review of renal transplant recipients with graft failure found the proportion of allograft dysfunction due to cardiorenal syndrome to be 4.6%, suggesting that venous congestion is an important cause of allograft dysfunction [25]. Functional tricuspid regurgitation in the setting of RV dilation and dysfunction can further increase venous pressure and potentially affect renal perfusion pressure. Hypotension as a result of autonomic dysfunction, vascular calcification, and low cardiac output could be contributing to graft failure as well. Additional studies are needed to clarify these mechanisms. Our findings suggest that RV assessment by TTE could be extremely useful in identifying patients who require further cardiovascular optimization and work-up, including diagnostic testing and adjustment of ultrafiltration goals, prior to renal transplantation.

While prior studies in the pretransplant population have focused on RVSP for PH screening, it is important to note that RVSP could not be measured in the majority of patients in our real-world sample. An incomplete or poor-quality tricuspid regurgitation Doppler envelope often precludes RVSP measurement. Common reasons for this include absence of tricuspid regurgitation, eccentricity of the tricuspid regurgitation jet, and patient obesity. While an elevated RVSP should raise suspicion for PH, an echocardiogram report that omits RVSP or includes a “normal” RVSP based on a poor-quality signal should not be considered reassuring. RVSP and RV basal diameter were moderately correlated in our population.

When a TTE is ordered for a pretransplant patient, we recommend that the ordering physician specifically request detailed comments on RV size and function. Because of the right ventricle’s unique shape – conceptualized as a pyramid, crescent, or baseball glove, depending upon one’s perspective (Fig. 4) – it is very difficult to model geometrically. No single linear or 2-dimensional parameter can adequately determine whether the right ventricle is dilated or dysfunctional. Assessment of RV size in multiple echocardiographic views and in relation to left ventricular size is critically important. As such, assessment of the right ventricle by a thoughtful and experienced echocardiographer is highly desirable.

**Limitations**

This was a retrospective, single-center study evaluating a relatively small population of patients. RV dimensions and function are volume-dependent, so the timing of each echocardiogram in relation to dialysis could have impacted the results. At the time these TTEs were obtained, tricuspid annular plane systolic excursion (a M-mode echocardiographic parameter) and tricuspid annular S’ velocity (a tissue Doppler parameter) were not standard at our institution, although they are recommended for RV function assessment per current guidelines [10]. Finally, in an effort to emulate real-world practice, we

---

**Fig. 4.** Complex shape of the RV. **a** In this parasternal short-axis view on TTE, the RV appears to be a crescent wrapped around the LV. **b** In this RV 3-chamber view on cardiovascular magnetic resonance, the RV and RVOT appear like a baseball glove gripping the Ao. RA. **c** In this apical 4-chamber view on TTE, the RV looks like a triangle or sail. This is perhaps the most important view for assessment of RV size and function on TTE. LA, left atrium; RV, right ventricle; TTE, transthoracic echocardiography; LV, left ventricle; RVOT, right ventricular outflow tract; Ao, aorta; RA, right atrium.
chose not to exclude any patients with limited TTE image quality, though individual data points were omitted when accurate measurements could not be made.

Conclusions

In this retrospective study, we have shown that RV dilation and dysfunction on pretransplant TTE are associated with adverse outcomes following renal transplant, including delayed graft function, graft failure, and all-cause mortality. Assessment of RV size and function by TTE could be invaluable in risk stratification prior to renal transplantation. Large, prospective, multicenter studies are needed to corroborate these findings.

Statement of Ethics

The University of Michigan institutional review board approved the retrospective study as part of a multivariate analysis of outcomes of the University of Michigan transplantation program.

References

1. Glicklich D, Vohra P. Cardiovascular risk assessment before and after kidney transplantation. Cardiol Rev. 2014;22(4):153–62.
2. Lentine KL, Costa SP, Weir MR, Robb JF, Fleisher LA, Kasiske BL, et al. Cardiac disease evaluation and management among kidney and liver transplantation candidates: a scientific statement from the American Heart Association and the American College of cardiology foundation. J Am Coll Cardiol. 2012; 60(5):434–80.
3. Collins AJ, Foley RN, Chavers B, Gilbertson D, Herzog C, Ishani A, et al. US renal data system 2013 annual data report. Am J Kidney Dis. 2014;63(1 Suppl):A7.
4. Bolignano D, Pisano A, Coppolino G, Tripepi GL, D’Arrigo G. Pulmonary hypertension predicts adverse outcomes in renal patients: a systematic review and meta-analysis. Ther Apher Dial. 2019;23(4):369–84.
5. Bangaswami J, Bhatla V, Blair JEA, Chang TI, Costa S, Lentine KL, et al. Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation. 2019;139(16):e840–e78.
6. Lentine KL, Villines TC, Axelrod D, Kaviratne S, Weir MR, Costa SP. Evaluation and management of pulmonary hypertension in kidney transplant candidates and recipients: concepts and controversies. Transplantation. 2017;101(1):166–81.
7. McLaughlin VV, Shah SJ, Souza R, Humbert M. Management of pulmonary arterial hypertension. J Am Coll Cardiol. 2015;65(18):1976–97.
8. Baggen VJ, Leiner T, Post MC, van Dijk AP, Roos-Hesselink JW, Boersma E, et al. Cardiac magnetic resonance findings predicting mortality in patients with pulmonary arterial hypertension: a systematic review and meta-analysis. Eur Radiol. 2016;26(11):3771–80.
9. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification: a report from the American Society of echocardiography’s guidelines and standards committee and the chamber quantification writing group, developed in conjunction with the European Association of echocardiography, a branch of the European Society of cardiology. J Am Soc Echocardiogr. 2005;18(12):1400–63.
10. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the American Association of cardiovascular imaging. J Am Soc Echocardiogr. 2015;28(1):1–39.e14.
11. Zoghbi WA, Adams D, Bonow RO, Enriquez-Sarano M, Foster E, Grayburn PA, et al. Recommendations for noninvasive evaluation of native valvular regurgitation: a report from the American Society of echocardiography developed in collaboration with the society for cardiovascular magnetic resonance. J Am Soc Echocardiogr. 2017;30(4):303–71.
12. Yigla M, Nakhoul F, Sabag A, Tov N, Gorevich B, Abassi Z, et al. Pulmonary hypertension in patients with end-stage renal disease. Chest. 2003;123(5):1577–82.
13. Abdelwhab S, Elshinnawy S. Pulmonary hypertension in chronic renal failure patients. Am J Nephrol. 2008;28(6):990–7.
14. Nakhoul F, Yigla M, Gilman R, Reiser SA, Abassi Z. The pathogenesis of pulmonary hypertension in haemodialysis patients via arterio-venous access. Nephrol Dial Transplant. 2005;20(8):1686–92.
15. Bolignano D, Rastelli S, Agarwal R, Fliser D, Massy Z, Ortiz A, et al. Pulmonary hypertension in CKD. Am J Kidney Dis. 2013;61(4):612–22.
16. Stallworthy EJ, Pilmore HL, Webster MW, Sidhu KK, Curry EM, Brown P, et al. Do echocardiographic parameters predict mortality in patients with end-stage renal disease? Transplantation. 2013;95(10):1225–32.

Conflict of Interest Statement

Megan Joseph: None. Francis Tinney: None. Abhijit Naik: None. Raviprasanna Parasuraman: None. Milagros Samaniego-Picota: None. Nicole Bhave: None.

Funding Sources

There was no specific funding for this project.

Author Contributions

Megan Joseph, MD, participated in the writing of the paper, performance of the research, and data analysis. Francis Tinney, MD, participated in the performance of the research and data analysis. Abhijit Naik, MD, participated in the writing of the paper and data analysis. Raviprasanna Parasuraman, MD, participated in the writing of the paper and data analysis. Milagros Samaniego-Picota, MD, participated in the writing of the paper and data analysis. Nicole Bhave, MD, participated in research design, echocardiographic analysis, writing of the paper, and data analysis.
17 Zlotnick DM, Axelrod DA, Chobanian MC, Friedman S, Brown J, Catherwood E, et al. Non-invasive detection of pulmonary hypertension prior to renal transplantation is a predictor of increased risk for early graft dysfunction. Nephrol Dial Transplant. 2010; 25(9):3090–6.
18 Issa N, Krowka MJ, Griffin MD, Hickson LJ, Stegall MD, Cosio FG. Pulmonary hypertension is associated with reduced patient survival after kidney transplantation. Transplantation. 2008;86(10):1384–8.
19 Caughey MC, Detwiler RK, Sivak JA, Rose-Jones LJ, Kshirsagar AV, Hinderliter AL. Five-year outcomes of pulmonary hypertension with and without elevated left atrial pressure in patients evaluated for kidney transplantation. Transplantation. 2020 Oct;104(10):2113–9.
20 Hickson LJ, Negrotto SM, Onuigbo M, Scott CG, Rule AD, Norby SM, et al. Echocardiography criteria for structural heart disease in patients with end-stage renal disease initiating hemodialysis. J Am Coll Cardiol. 2016; 67(10):1173–82.
21 Foley RN, Gilbertson DT, Murray T, Collins AJ. Long interdialytic interval and mortality among patients receiving hemodialysis. N Engl J Med. 2011;365(12):1099–107.
22 Tsilonis K, Sarafidis PA, Kamperidis V, Loutradis C, Georgianos PI, Imprialos K, et al. Echocardiographic parameters during long and short interdialytic intervals in hemodialysis patients. Am J Kidney Dis. 2016;68(5):772–81.
23 Sun M, Cao X, Guo Y, Tan X, Dong L, Pan C, et al. Long-term impacts of hemodialysis on the right ventricle: assessment via 3-dimensional speckle-tracking echocardiography. Clin Cardiol. 2018;41(1):87–95.
24 Samarendra P, Ramkumar M, Sharma V, Kumar S. Cardiorenal syndrome in renal transplant recipients: It’s the fistula at fault: a case series. Clin Transplant. 2018;32(11):e13417.
25 Waiser J, Knebel F, Rudolph B, Wu K, Müller E, Sanad W, et al. Renal allograft loss caused by cardiorenal syndrome: frequency and diagnosis. Transplantation. 2015;99(6):1208–15.